Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial

Edmund J Lewis, Julia B Lewis, Tom Greene, Lawrence G Hunsicker, Tomas Berl, Marc A Pohl, Dick de Zeeuw, Hiddo Lambers Heerspink, Richard D Rohde, Robert C Atkins, Anne T Reutens, David K Packham, Itamar Raz, Collaborative Study Group, Birger Thorsteinsson

107 Citationer (Scopus)

Abstract

Sulodexide, a heterogenous group of sulfated glycosaminoglycans, includes low-molecular-weight heparin (~80% ± 8%), high-molecular-weight heparin (~5% ± 3%), and dermatan (~20% ± 8%), with a mean molecular weight of ~9 kDa. The drug is absorbed orally and has no anticoagulant effect in the doses used. Small preliminary studies consistently showed sulodexide to be associated with decreased albuminuria in patients with diabetes.
OriginalsprogEngelsk
TidsskriftAmerican Journal of Kidney Diseases
Vol/bind58
Udgave nummer5
Sider (fra-til)729-36
Antal sider8
ISSN0272-6386
DOI
StatusUdgivet - 2011

Fingeraftryk

Dyk ned i forskningsemnerne om 'Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater